Bayerische Motoren Werke (OTCMKTS:BAMXF) Receives Buy Rating from Credit Suisse Group

Share on StockTwits

Bayerische Motoren Werke (OTCMKTS:BAMXF)‘s stock had its “buy” rating reaffirmed by equities research analysts at Credit Suisse Group in a research report issued to clients and investors on Thursday, AnalystRatings.com reports. They currently have a $90.00 target price on the stock. Credit Suisse Group’s price target indicates a potential upside of 21.46% from the stock’s previous close.

BAMXF has been the topic of several other research reports. UBS Group restated a “hold” rating on shares of Daimler in a research note on Wednesday, May 22nd. Jefferies Financial Group restated a “hold” rating and set a $75.00 price target on shares of Bayerische Motoren Werke in a research note on Tuesday, May 7th. Deutsche Bank restated a “buy” rating and set a $80.00 price target on shares of Bayerische Motoren Werke in a research note on Monday, July 8th. Kepler Capital Markets restated a “sell” rating and set a $63.00 price target on shares of Bayerische Motoren Werke in a research note on Wednesday, June 26th. Finally, Sanford C. Bernstein restated a “hold” rating and set a $85.00 price target on shares of Bayerische Motoren Werke in a research note on Tuesday, May 7th. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $75.90.

Shares of Bayerische Motoren Werke stock traded down $0.85 during trading on Thursday, hitting $74.10. 2,311 shares of the stock traded hands, compared to its average volume of 3,280. The stock has a market cap of $44.60 billion, a price-to-earnings ratio of 5.76, a P/E/G ratio of -3.42 and a beta of 1.17. The company has a current ratio of 1.15, a quick ratio of 0.93 and a debt-to-equity ratio of 1.20. Bayerische Motoren Werke has a 52-week low of $68.00 and a 52-week high of $102.10. The firm’s fifty day moving average is $72.28.

Bayerische Motoren Werke (OTCMKTS:BAMXF) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.89 EPS for the quarter. The firm had revenue of $25.51 billion for the quarter. Bayerische Motoren Werke had a return on equity of 9.31% and a net margin of 5.56%. On average, equities research analysts anticipate that Bayerische Motoren Werke will post 10.45 earnings per share for the current fiscal year.

About Bayerische Motoren Werke

Bayerische Motoren Werke Aktiengesellschaft, together with its subsidiaries, develops, manufactures, and sells automobiles and motorcycles, and spare parts and accessories worldwide. The company operates through Automotive, Motorcycles, and Financial Services segments. The Automotive segment develops, manufactures, assembles, and sells automobiles and off-road vehicles under the BMW, MINI, and Rolls-Royce brands; and spare parts and accessories, as well as offers mobility services.

Recommended Story: What is the significance of a dead cat bounce?

Analyst Recommendations for Bayerische Motoren Werke (OTCMKTS:BAMXF)

Receive News & Ratings for Bayerische Motoren Werke Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayerische Motoren Werke and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.